首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

2103074

全球視神經脊髓炎臨床試驗現況：趨勢與分析（2026 年版）

Global Neuromyelitis Optica Clinical Trials Landscape: Developments and Analysis, 2026 Update

出版日期: 2026年07月17日 | 出版商:

Knowledge Sourcing Intelligence | 英文 175 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

視神經脊髓炎（NMO），也稱為視神經脊髓炎頻譜障礙（NMOSD），是一種罕見的自體免疫發炎疾病，主要涉及中樞神經系統，其特徵是反覆發作，涉及視神經、脊髓和腦幹。此疾病主要與靶向水通道蛋白4（AQP4）的抗體相關，會導致嚴重的神經功能障礙、視力喪失、癱瘓和長期殘疾。傳統的治療方案僅限於廣泛的免疫抑制療法，但近年來，標靶生技藥品和精準免疫療法的研發極大地改變了治療模式。

臨床試驗趨勢分析能夠全面深入了解正在進行和已完成的研究、臨床實驗中的療法、研發管線進展、監管趨勢、試驗結果以及新興治療策略。對於希望了解視神經脊髓炎譜系疾病（NMOSD）市場未來商機的製藥公司、生技公司、投資人、醫療專業人員和研究機構而言，這些分析的重要性日益凸顯。

市場促進因素

臨床研究活動活性化

市場成長的主要驅動力之一是針對自體免疫神經系統疾病的臨床研究顯著增加。隨著視神經脊髓炎譜系障礙（NMOSD）被公認為一種獨立的疾病，標靶治療的研發正在加速，評估新療法的臨床研究數量也不斷增加。

多國臨床試驗的增加，使人們對疾病進展、治療反應和長期患者預後有了更深入的了解。

標靶生物療法的進展

標靶生物製藥的出現從根本上改變了視神經脊髓炎譜系障礙（NMOSD）的治療模式。針對補體蛋白、B細胞、白細胞介素路徑和其他免疫介導機制的療法在降低復發率和延緩疾病進展方面顯示出顯著療效。

隨著下一代生物製藥的臨床開發不斷推進，NMOSD 的臨床研究也獲得了大量投資。

加深我們對疾病病理生理學的理解

免疫學和生物標記研究的進展加深了我們對視神經脊髓炎譜系疾病（NMOSD）潛在機制的理解。水通道蛋白4抗體及其相關免疫路徑的發現，使得開發更具標靶性和有效性的治療方法成為可能。

科學知識的累積促進了精準醫療方法的擴展，並改進了臨床試驗的設計。

支持性的法規環境

監管機構持續鼓勵罕見疾病治療藥物的研發，包括孤兒藥認定、快速核准流程和監管激勵措施。這些措施有助於加速臨床研發項目，並刺激對視神經脊髓炎譜系疾病（NMOSD）研究的投資。

市場限制因素

患者數量少

由於視神經脊髓炎譜系障礙（NMOSD）是一種罕見的神經系統疾病，全球患者數量相對較少。因此，患者招募可能較為困難，導致臨床試驗週期延長。

高昂的臨床開發成本

生物製藥和先進免疫療法的開發需要在研究、生產、監管合規和長期安全監測方面進行大量投資。

複雜的測試設計要求

NMOSD 的臨床試驗通常需要較長的追蹤期來評估復發預防、殘疾進展和長期治療安全性，這增加了研發的複雜性和成本。

未來管道演進
新的科學趨勢
下一代治療方法
具有高潛力的機制和模式
預測期內的競爭前景
給開發人員的策略建議
主要公司簡介
- Roche Holding AG
- Chugai Pharmaceutical Co., Ltd.
- Alexion Pharmaceuticals, Inc.
- AstraZeneca PLC
- Amgen Inc.
- Horizon Therapeutics plc
- Viela Bio, Inc.
- HanAll Biopharma Co., Ltd.
- Immunovant, Inc.
- Argenx SE
- 戰略展望

第14章：調查方法與資料框架

簡介目錄

Product Code: KSI-008870

Neuromyelitis Optica (NMO), also known as Neuromyelitis Optica Spectrum Disorder (NMOSD), is a rare autoimmune inflammatory disease of the central nervous system characterized by recurrent attacks affecting the optic nerves, spinal cord, and brainstem. The disease is primarily associated with antibodies targeting aquaporin-4 (AQP4), leading to severe neurological damage, vision loss, paralysis, and long-term disability. Historically, treatment options were limited to broad immunosuppressive therapies; however, recent scientific advances have transformed the therapeutic landscape through the development of targeted biologics and precision immunotherapies.

Clinical trial landscape analysis provides comprehensive insights into ongoing and completed studies, investigational therapies, pipeline progression, regulatory developments, trial outcomes, and emerging treatment strategies. These analyses are increasingly important for pharmaceutical companies, biotechnology firms, investors, healthcare providers, and research organizations seeking to understand future opportunities within the NMOSD market.

Market Drivers

Increasing Clinical Research Activity

One of the primary drivers of market growth is the significant increase in clinical research focused on autoimmune neurological disorders. Growing recognition of NMOSD as a distinct disease entity has accelerated the development of targeted therapies and expanded the number of clinical studies evaluating novel treatment approaches.

The increasing number of multinational clinical trials is improving understanding of disease progression, treatment response, and long-term patient outcomes.

Advancements in Targeted Biologic Therapies

The emergence of targeted biologic therapies has fundamentally transformed the NMOSD treatment landscape. Therapies targeting complement proteins, B cells, interleukin pathways, and other immune-mediated mechanisms have demonstrated significant efficacy in reducing relapse rates and disease progression.

Continued clinical development of next-generation biologics is driving substantial investment in NMOSD clinical research.

Growing Understanding of Disease Pathophysiology

Advances in immunology and biomarker research have improved understanding of the mechanisms underlying NMOSD. The identification of aquaporin-4 antibodies and related immune pathways has enabled the development of more targeted and effective therapies.

This growing scientific knowledge is supporting the expansion of precision medicine approaches and improving clinical trial design.

Supportive Regulatory Environment

Regulatory agencies continue to encourage rare disease drug development through orphan drug designations, expedited review pathways, and regulatory incentives. These initiatives are helping accelerate clinical development programs and encourage investment in NMOSD research.

Market Restraints

Limited Patient Population

As a rare neurological disorder, NMOSD affects a relatively small patient population globally. This can make patient recruitment challenging and may extend clinical trial timelines.

High Clinical Development Costs

The development of biologics and advanced immunotherapies requires significant investment in research, manufacturing, regulatory compliance, and long-term safety monitoring.

Complex Trial Design Requirements

Clinical trials in NMOSD often require extended follow-up periods to evaluate relapse prevention, disability progression, and long-term treatment safety, increasing development complexity and costs.

Clinical Trial and Technology Insights

The global NMOSD clinical trials landscape can be segmented by development phase, therapeutic modality, mechanism of action, sponsor type, and geography.

By development phase, the market includes preclinical studies, Phase I trials, Phase II trials, Phase III trials, extension studies, and post-marketing investigations. Late-stage clinical programs continue to attract significant attention due to their potential to introduce new treatment options into the market.

By therapeutic modality, the landscape includes monoclonal antibodies, complement inhibitors, B-cell targeted therapies, interleukin inhibitors, immunosuppressive agents, cell-based therapies, and emerging biologic treatments. Monoclonal antibody therapies currently represent one of the most active areas of clinical development.

By mechanism of action, investigational therapies target complement cascade inhibition, B-cell depletion, cytokine modulation, antibody neutralization, immune tolerance induction, and neuroprotection pathways.

By sponsor type, the market includes pharmaceutical companies, biotechnology firms, academic institutions, research organizations, government agencies, and collaborative clinical research networks.

Technological advancements such as biomarker-guided patient selection, precision medicine approaches, artificial intelligence-assisted trial design, digital patient monitoring, and real-world evidence integration are improving clinical trial efficiency and accelerating therapeutic development.

Clinical Development Trends

Clinical development activity within NMOSD has increased significantly in recent years due to the success of targeted therapies and growing understanding of disease biology.

Current research efforts focus on:

Reducing relapse frequency and disease progression.
Improving long-term neurological outcomes.
Developing safer and more selective immunotherapies.
Expanding treatment options for antibody-positive and antibody-negative patient populations.
Enhancing personalized treatment strategies through biomarker-driven approaches.

In addition to relapse prevention, researchers are increasingly investigating therapies capable of promoting neurological recovery, reducing disability, and improving quality of life.

Regional Insights

North America remains a leading region for NMOSD clinical research due to strong academic research networks, advanced healthcare infrastructure, favorable regulatory frameworks, and substantial investment in rare disease therapeutics. The United States accounts for a significant share of ongoing clinical trial activity.

Europe represents another major market supported by collaborative research initiatives, established rare disease programs, and active participation in multinational clinical studies.

Asia-Pacific is expected to experience rapid growth in clinical research activity due to increasing healthcare investments, expanding clinical trial capabilities, and growing awareness of autoimmune neurological disorders. Countries such as Japan, China, South Korea, and Australia are becoming increasingly important contributors to global NMOSD research.

Latin America and the Middle East & Africa are gradually expanding participation in international clinical development programs, supported by improving healthcare infrastructure and growing interest in rare disease research.

Competitive Landscape

The NMOSD clinical trials landscape is characterized by participation from major pharmaceutical companies, biotechnology innovators, academic medical centers, and research organizations focused on autoimmune and neurological diseases.

Market participants are actively pursuing strategies aimed at improving efficacy, reducing relapse risk, enhancing safety profiles, and expanding treatment accessibility. Strategic collaborations, licensing agreements, research partnerships, and acquisitions continue to support pipeline advancement and accelerate therapeutic innovation.

Companies are increasingly investing in next-generation biologics, precision medicine technologies, and novel immunomodulatory approaches to strengthen their competitive positions within the NMOSD market.

Future Outlook

The future of the NMOSD clinical trials landscape is expected to be driven by continued innovation in immunology, biologic drug development, biomarker discovery, and personalized medicine. Advances in disease understanding are likely to support the development of more targeted therapies capable of delivering durable disease control with improved safety profiles.

Emerging technologies including artificial intelligence, genomic analytics, digital health platforms, and real-world evidence systems are expected to further optimize clinical trial design and accelerate drug development timelines.

As additional therapies progress through late-stage clinical development, the NMOSD treatment landscape is expected to become increasingly competitive and diversified.

Conclusion

The global Neuromyelitis Optica clinical trials landscape, developments, and analysis market is poised for significant growth through 2035, supported by expanding research activity, increasing investment in rare neurological disorders, advancements in targeted biologics, and growing adoption of precision medicine approaches. While challenges related to patient recruitment, development costs, and trial complexity remain, continued innovation across immunotherapy, biomarker research, and clinical trial technologies is expected to transform the future of NMOSD treatment. As new therapies advance through the clinical pipeline, the market is likely to experience substantial improvements in treatment outcomes and long-term disease management.

Key Benefits of this Report

Insightful Analysis: Comprehensive evaluation of NMOSD clinical trials, emerging therapies, and development trends.
Competitive Landscape: Understand sponsor activity, pipeline progression, and strategic industry developments.
Market Drivers and Future Trends: Assess factors shaping future clinical research and therapeutic innovation.
Actionable Recommendations: Support investment decisions, clinical development planning, and partnership strategies.
Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, researchers, healthcare providers, investors, and policy stakeholders.

What Businesses Use Our Reports For

Clinical trial monitoring, pipeline benchmarking, competitive intelligence, licensing evaluations, investment analysis, partnership assessments, portfolio planning, regulatory strategy development, and market opportunity identification.

Report Coverage

Historical data from 2021 to 2025, Base year 2025, and Forecast years from 2026 to 2035
Clinical trial analysis by development phase, therapy type, mechanism of action, and sponsor category
Assessment of ongoing, completed, and emerging clinical development programs
Competitive intelligence, regulatory developments, and strategic industry activity
Future innovation trends, pipeline opportunities, and market outlook.

1. Executive Summary

1.1 Report Scope and Objectives
1.2 Neuromyelitis Optica Clinical Development Snapshot
- 1.2.1 Current Pipeline Size
- 1.2.2 Assets by Development Phase
- 1.2.3 Pipeline by Mechanism of Action
- 1.2.4 Pipeline by Modality
1.3 Key Clinical and Commercial Insights
1.4 Emerging Trends and Innovation Themes
1.5 Strategic Outlook

2. Pipeline Overview

2.1 Introduction to Neuromyelitis Optica Pipeline
2.2 Pipeline Evolution and Historical Trends
- 2.2.1 Historical Asset Growth
- 2.2.2 Clinical Development Milestones
- 2.2.3 Regulatory Milestones
2.3 Current Pipeline Landscape
- 2.3.1 Total Number of Pipeline Assets
- 2.3.2 Active versus Discontinued Assets
- 2.3.3 Pipeline Maturity Assessment
2.4 Pipeline Distribution by Development Stage
- 2.4.1 Preclinical Assets
- 2.4.2 Phase I Assets
- 2.4.3 Phase II Assets
- 2.4.4 Phase III Assets
- 2.4.5 Filed / Under Regulatory Review Assets
2.5 Pipeline Distribution by Developer Type
- 2.5.1 Large Pharmaceutical Companies
- 2.5.2 Biotechnology Companies
- 2.5.3 Academic and Research Institutions
- 2.5.4 Collaborative Development Programs
2.6 Pipeline Heat Map and Development Trends

3. Disease and Unmet Need Analysis

3.1 Disease Overview
- 3.1.1 Disease Definition
- 3.1.2 Epidemiology Overview
- 3.1.3 Disease Burden
3.2 Disease Pathophysiology
- 3.2.1 Autoimmune Mechanisms
- 3.2.2 Role of Aquaporin-4 Antibodies
- 3.2.3 Complement Activation Pathways
- 3.2.4 Cytokine and Immune Signaling
3.3 Current Treatment Landscape
- 3.3.1 Approved Therapies
- 3.3.2 Standard of Care
- 3.3.3 Treatment Algorithms
3.4 Limitations of Existing Therapies
- 3.4.1 Relapse Prevention Challenges
- 3.4.2 Safety Concerns
- 3.4.3 Long-Term Disease Management Gaps
3.5 Unmet Clinical Needs
- 3.5.1 Novel Mechanisms
- 3.5.2 Improved Efficacy
- 3.5.3 Better Safety Profiles
- 3.5.4 Patient Convenience and Adherence

4. Mechanism and Modality Landscape

4.1 Mechanism of Action Landscape
- 4.1.1 Complement Pathway Inhibitors
- 4.1.2 B-Cell Targeted Therapies
- 4.1.3 Interleukin Pathway Inhibitors
- 4.1.4 Fc Receptor Targeting Agents
- 4.1.5 Other Emerging Mechanisms
4.2 Mechanism-Based Pipeline Clustering
- 4.2.1 Established Mechanisms
- 4.2.2 Novel Mechanisms
- 4.2.3 First-in-Class Assets
- 4.2.4 Best-in-Class Candidates
4.3 Modality Landscape
- 4.3.1 Monoclonal Antibodies
- 4.3.2 Small Molecules
- 4.3.3 Fusion Proteins
- 4.3.4 Cell Therapies
- 4.3.5 Gene Therapies
- 4.3.6 RNA-Based Therapies
4.4 Innovation Trends
- 4.4.1 Next-Generation Immunotherapies
- 4.4.2 Precision Medicine Approaches
- 4.4.3 Combination Treatment Strategies

5. Clinical Development Intelligence

5.1 Clinical Trial Landscape Overview
5.2 Trial Activity by Development Phase
- 5.2.1 Early-Stage Trials
- 5.2.2 Mid-Stage Trials
- 5.2.3 Late-Stage Trials
5.3 Clinical Trial Design Benchmarking
- 5.3.1 Trial Design Types
- 5.3.2 Sample Size Analysis
- 5.3.3 Study Duration Analysis
- 5.3.4 Randomization Trends
- 5.3.5 Control Arm Strategies
5.4 Endpoint Analysis
- 5.4.1 Primary Endpoints
- 5.4.2 Secondary Endpoints
- 5.4.3 Biomarker Endpoints
- 5.4.4 Patient Reported Outcomes
5.5 Recruitment and Enrollment Trends
- 5.5.1 Enrollment Timelines
- 5.5.2 Geographic Recruitment Patterns
- 5.5.3 Trial Completion Rates
5.6 Clinical Success and Failure Trends
- 5.6.1 Successful Development Strategies
- 5.6.2 Clinical Failures and Lessons Learned
- 5.6.3 Trial Termination Trends

6. Global Neuromyelitis Optica Clinical Trials Landscape Report Segmentation

6.1 By Clinical Trial Phase
- 6.1.1 Preclinical & Phase I
- 6.1.2 Phase II & Phase III or Combined
- 6.1.3 Phase IV & Post-Marketing
6.2 By Mechanism of Action
- 6.2.1 B-cell depletion
- 6.2.2 IL-6 receptor blockade
- 6.2.3 Complement inhibition
- 6.2.4 Others
6.3 By Sponsor Type
- 6.3.1 Pharmaceutical & Biotech Companies
- 6.3.2 Academic & Research Institutes

7. Probability of Success and Risk Analysis

7.1 Clinical Development Risk Framework
7.2 Historical Phase Transition Rates
- 7.2.1 Preclinical to Phase I
- 7.2.2 Phase I to Phase II
- 7.2.3 Phase II to Phase III
- 7.2.4 Phase III to Approval
7.3 Probability of Success Modeling
- 7.3.1 Asset-Level Probability Analysis
- 7.3.2 Mechanism-Based Success Probability
- 7.3.3 Modality-Based Success Probability
7.4 Attrition Analysis
- 7.4.1 Historical Attrition Trends
- 7.4.2 Reasons for Failure
- 7.4.3 Risk Factors by Phase
7.5 Risk-Adjusted Pipeline Assessment
- 7.5.1 Risk-Adjusted Asset Valuation
- 7.5.2 Risk-Weighted Commercial Opportunity

8. Launch Timeline and Commercial Potential

8.1 Regulatory Outlook
- 8.1.1 Anticipated Regulatory Milestones
- 8.1.2 Approval Timeline Forecast
8.2 Launch Timeline Assessment
- 8.2.1 Near-Term Launches
- 8.2.2 Mid-Term Launches
- 8.2.3 Long-Term Launches
8.3 Commercial Opportunity Analysis
- 8.3.1 Market Potential
- 8.3.2 Peak Sales Potential
- 8.3.3 Revenue Forecasting Assumptions
8.4 Competitive Launch Sequencing
- 8.4.1 First Mover Advantage
- 8.4.2 Competitive Entry Timing
- 8.4.3 Market Share Outlook

9. Competitive Pipeline Landscape

9.1 Competitive Overview
9.2 Company-Wise Pipeline Strength
9.3 Pipeline Concentration Analysis
9.4 Leader versus Challenger Assessment
9.5 Competitive Positioning Matrix
9.6 Innovation Leadership Analysis
9.7 Strategic Benchmarking of Developers
9.8 Partnership and Collaboration Trends

10. Geographic Analysis

10.1 North America
- 10.1.1 Clinical Trial Activity
- 10.1.2 Regulatory Environment
- 10.1.3 Innovation Ecosystem
10.2 Europe
- 10.2.1 Clinical Trial Activity
- 10.2.2 Regulatory Environment
- 10.2.3 Innovation Ecosystem
10.3 Asia-Pacific
- 10.3.1 Clinical Trial Activity
- 10.3.2 Regulatory Environment
- 10.3.3 Innovation Ecosystem
10.4 Latin America
- 10.4.1 Clinical Trial Activity
- 10.4.2 Regulatory Environment
- 10.4.3 Innovation Ecosystem
10.5 Middle East and Africa
- 10.5.1 Clinical Trial Activity
- 10.5.2 Regulatory Environment
- 10.5.3 Innovation Ecosystem

11. Key Countries Analysis

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 China
11.9 Japan
11.10 India
11.11 South Korea
11.12 Australia
11.13 Brazil
11.14 Mexico
11.15 Saudi Arabia
11.16 South Africa

12. Deals and Investment Landscape

12.1 Licensing Agreements
- 12.1.1 Regional Licensing Deals
- 12.1.2 Global Licensing Transactions
12.2 Co-Development and Collaboration Agreements
12.3 Mergers and Acquisitions
- 12.3.1 Asset Acquisitions
- 12.3.2 Company Acquisitions
12.4 Financing and Investment Trends
- 12.4.1 Venture Capital Funding
- 12.4.2 Private Equity Investments
- 12.4.3 Public Market Financing
12.5 Strategic Investment Themes

13. Future Outlook and Strategic Insights

13.1 Future Pipeline Evolution
13.2 Emerging Scientific Trends
13.3 Next Generation Therapeutic Approaches
13.4 High Potential Mechanisms and Modalities
13.5 Competitive Outlook Through Forecast Period
13.6 Strategic Recommendations for Developers
13.7 Key Companies Profiled
- 13.7.1 Roche Holding AG
  - 13.7.1.1 Company Overview
  - 13.7.1.2 Neuromyelitis Optica Pipeline Portfolio
  - 13.7.1.3 Clinical Development Strategy
  - 13.7.1.4 Competitive Positioning
  - 13.7.1.5 Strategic Outlook
- 13.7.2 Chugai Pharmaceutical Co., Ltd.
  - 13.7.2.1 Company Overview
  - 13.7.2.2 Neuromyelitis Optica Pipeline Portfolio
  - 13.7.2.3 Clinical Development Strategy
  - 13.7.2.4 Competitive Positioning
  - 13.7.2.5 Strategic Outlook
- 13.7.3 Alexion Pharmaceuticals, Inc.
  - 13.7.3.1 Company Overview
  - 13.7.3.2 Neuromyelitis Optica Pipeline Portfolio
  - 13.7.3.3 Clinical Development Strategy
  - 13.7.3.4 Competitive Positioning
  - 13.7.3.5 Strategic Outlook
- 13.7.4 AstraZeneca PLC
  - 13.7.4.1 Company Overview
  - 13.7.4.2 Neuromyelitis Optica Pipeline Portfolio
  - 13.7.4.3 Clinical Development Strategy
  - 13.7.4.4 Competitive Positioning
  - 13.7.4.5 Strategic Outlook
- 13.7.5 Amgen Inc.
  - 13.7.5.1 Company Overview
  - 13.7.5.2 Neuromyelitis Optica Pipeline Portfolio
  - 13.7.5.3 Clinical Development Strategy
  - 13.7.5.4 Competitive Positioning
  - 13.7.5.5 Strategic Outlook
- 13.7.6 Horizon Therapeutics plc
  - 13.7.6.1 Company Overview
  - 13.7.6.2 Neuromyelitis Optica Pipeline Portfolio
  - 13.7.6.3 Clinical Development Strategy
  - 13.7.6.4 Competitive Positioning
  - 13.7.6.5 Strategic Outlook
- 13.7.7 Viela Bio, Inc.
  - 13.7.7.1 Company Overview
  - 13.7.7.2 Neuromyelitis Optica Pipeline Portfolio
  - 13.7.7.3 Clinical Development Strategy
  - 13.7.7.4 Competitive Positioning
  - 13.7.7.5 Strategic Outlook
- 13.7.8 HanAll Biopharma Co., Ltd.
  - 13.7.8.1 Company Overview
  - 13.7.8.2 Neuromyelitis Optica Pipeline Portfolio
  - 13.7.8.3 Clinical Development Strategy
  - 13.7.8.4 Competitive Positioning
  - 13.7.8.5 Strategic Outlook
- 13.7.9 Immunovant, Inc.
  - 13.7.9.1 Company Overview
  - 13.7.9.2 Neuromyelitis Optica Pipeline Portfolio
  - 13.7.9.3 Clinical Development Strategy
  - 13.7.9.4 Competitive Positioning
  - 13.7.9.5 Strategic Outlook
- 13.7.10 Argenx SE
  - 13.7.10.1 Company Overview
  - 13.7.10.2 Neuromyelitis Optica Pipeline Portfolio
  - 13.7.10.3 Clinical Development Strategy
  - 13.7.10.4 Competitive Positioning
  - 13.7.10.5 Strategic Outlook
- 13.7.5 Strategic Outlook

14. Methodology and Data Framework

14.1 Research Methodology
14.2 Data Sources and Validation Framework
- 14.2.1 Clinical Trial Registries
- 14.2.2 Company Pipeline Disclosures
- 14.2.3 Regulatory Filings
- 14.2.4 Scientific Publications
14.3 Asset Inclusion and Exclusion Criteria
14.4 Phase Classification Methodology
14.5 Probability of Success Modeling Framework
14.6 Forecasting Assumptions
14.7 Limitations and Disclaimer
14.8 Glossary of Terms and Abbreviations

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

視神經脊髓炎治療市場報告：趨勢、預測和競爭分析（至2035年）

全球視神經脊髓炎治療研發管線分析 - 2026 年（第二季洞察與臨床試驗）

全球視神經脊髓炎流行病學分析與預測 - 2026 年

2026-2035年視神經脊髓炎全球藥物定價與報銷分析

全球視神經脊髓炎市場：競爭分析（2026 年）

全球視神經脊髓炎患者人數分析與預測（2026-2035 年）

全球視神經脊髓炎新興療法報告：2026年第二季度

全球視神經脊髓炎治療市場：策略性洞察與預測（2026-2035 年）

視神經脊髓炎市場：策略性洞察與預測（2026-2035 年）

FAQ

全球視神經脊髓炎臨床試驗現況：趨勢與分析（2026 年版）